Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
138.04B
Market cap138.04B
Price-Earnings ratio
18.77
Price-Earnings ratio18.77
Dividend yield
7.03%
Dividend yield7.03%
Average volume
45.06M
Average volume45.06M
High today
$24.52
High today$24.52
Low today
$24.22
Low today$24.22
Open price
$24.38
Open price$24.38
Volume
1.38M
Volume1.38M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$23.11
52 Week low$23.11

Stock Snapshot

With a market cap of 138.04B, Pfizer(PFE) trades at $24.22. The stock has a price-to-earnings ratio of 18.77 and currently yields dividends of 7.03%.

During the trading session on 2026-07-14, Pfizer(PFE) shares reached a daily high of $24.52 and a low of $24.22. At a current price of $24.22, the stock is +0.0% higher than the low and still -1.2% under the high.

Trading volume for Pfizer(PFE) stock has reached 1.38M, versus its average volume of 45.06M.

The stock's 52-week range extends from a low of $23.11 to a high of $28.75.

The stock's 52-week range extends from a low of $23.11 to a high of $28.75.

PFE News

Nasdaq 4h
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

Key Points Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally. Strong p...

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb
Nasdaq 16h
Pfizer Advances While Market Declines: Some Information for Investors

Pfizer (PFE) closed the latest trading day at $26.61, indicating a +0.3% change from the previous session's end. The stock's performance was ahead of the S&P 50...

Pfizer Advances While Market Declines: Some Information for Investors
MarketWatch 17h
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch

...

Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch

Analyst ratings

62%

of 29 ratings
Buy
31%
Hold
62.1%
Sell
6.9%

More PFE News

TipRanks 1d
Pfizer price target lowered to $30 from $34 at BMO Capital

BMO Capital lowered the firm’s price target on Pfizer (PFE) to $30 from $34 and keeps an Outperform rating on the shares as part of a broader research note prev...

Simply Wall St 3d
Pfizer Wins FDA Approval For First Platinum Free Bladder Cancer Regimen

FDA approved PADCEV (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) for adult patients with muscle-invasive bladder cancer. The regimen is cleared for...

Pfizer Wins FDA Approval For First Platinum Free Bladder Cancer Regimen
TipRanks 3d
Pfizer Juggles Fresh Trial Wins Amid Analyst Doubt

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has...

Nasdaq 4d
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?

Key Points Pfizer has regrouped in the GLP-1 space and is now working on a long-acting drug option. The company's update on the drug's development progress su...

Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?
TipRanks 4d
Pfizer’s Lorlatinib Lung Cancer Study Wraps Up, Offering Fresh Signals for PFE Investors

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...

Nasdaq 4d
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High

Shares of BridgeBio Pharma BBIO climbed to a 52-week high of $93.42 on Thursday after rival AstraZeneca's AZN late-stage clinical setback boosted investor confi...

How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
24/7 Wall St. 4d
McDonald's or Pfizer: One Offers Real Growth, One Just Pays You to Wait

McDonald’s or Pfizer: One Offers Real Growth, One Just Pays You to Wait By Trey Thoelcke Published Jul 10, 8:40AM EDT Quick Read MCD and PFE have each slipped...

McDonald's or Pfizer: One Offers Real Growth, One Just Pays You to Wait

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.